JLJason Lockrow

Jason Lockrow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason Lockrow has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phase 1 study of ABI ‐009 ( nab ‐rapamycin) for surgically refractory epilepsy ( RaSuRE )

    by Koko Hall, Russell Saneto, Stephanie Randle, Mark S. Wainwright, Patricia Berry, Sarah Leary, Ghayda Mirzaa, Jason Lockrow, Hannah Goldstein, Jeffrey Ojemann, et al.

    Objective: Seizures that are refractory to medical and surgical therapy increase the risk of morbidity and mortality in children with epilepsy. Novel therapeutic trials for this population remain sparse and suboptimal. This Phase 1 study evaluates the (1) safety, tolerability, and (2) preliminary efficacy of ABI‐009 ( nab‐ rapamycin) in children with medically and surgically refractory epilepsy. Methods: Children with medically intractable epilepsy and a history of resective surgery who experienced >8 seizures during the 30‐day baseline were included. Participants maintained their existing antiseizure medication regimens throughout the study. ABI‐009 was administered over 3 weeks using a 3 + 3 dose‐escalation design, with dosing cohorts of 5, 10, and 20 mg/m 2 . Treatment was then discontinued, and participants were observed for a 90‐day follow‐up period. Data were collected on seizure frequency, seizure type, adverse events, medical and laboratory assessments, the Quality of Life in Childhood Epilepsy (QOLCE), and the Nisonger Child Behavior Rating Form (NCBRF). Results: Twelve participants received ABI‐009 and completed all study visits. Seizure etiologies included tuberous sclerosis complex, focal cortical dysplasia, and hemimegalencephaly, although Mammalian target of rapamycin involvement was not required for inclusion. No doses were missed, and dose escalation progressed through all levels. The maximum tolerated dose was 20 mg/m 2 . All 12 participants experienced at least one treatment‐emergent adverse event (TEAE), with the majority being mild (80%). No participants withdrew from the study voluntarily or by necessity secondary to TEAEs, and there were no serious adverse events. The median change in the weekly seizure rate was a 37.6% reduction from baseline to treatment completion. The treatment response rate (≥25% seizure reduction) was 66.7%, and two participants achieved seizure freedom by follow‐up. Significance: ABI‐009 was deemed safe and tolerable in a pediatric cohort with medically and surgically refractory epilepsy, establishing a maximum tolerated dose of 20 mg/m 2 and showing early signs of efficacy.

  • Comparison of Cosyntropin, Vigabatrin, and Combination Therapy in New-Onset Infantile Spasms in a Prospective Randomized Trial

    by Kelly G. Knupp, Jason Coryell, Rani K. Singh, William D. Gaillard, Renée A. Shellhaas, Sookyong Koh, Wendy G. Mitchell, Chellamani Harini, John J. Millichap, Alison May, et al.

    Objective: In a randomized trial, we aimed to evaluate the efficacy of cosyntropin injectable suspension, 1 mg/mL, compared to vigabatrin for infantile spasms syndrome. An additional arm was included to assess the efficacy of combination therapy (cosyntropin and vigabatrin) compared with cosyntropin monotherapy. Methods: Children (2 months to 2 years) with new-onset infantile spasms syndrome and hypsarhythmia were randomized into 3 arms: cosyntropin, vigabatrin, and cosyntropin and vigabatrin combined. Daily seizures and adverse events were recorded, and EEG was repeated at day 14 to assess for resolution of hypsarhythmia. The primary outcome measure was the composite of resolution of hypsarhythmia and absence of clinical spasms at day 14. Fisher exact test was used to compare outcomes. Results: 37 children were enrolled and 34 were included in the final efficacy analysis (1 withdrew prior to treatment and 2 did not return seizure diaries). Resolution of both hypsarhythmia and clinical spasms was achieved in in 9 of 12 participants (75%) treated with cosyntropin, 1/9 (11%) vigabatrin, and 5/13 (38%) cosyntropin and vigabatrin combined. The primary comparison of cosyntropin versus vigabatrin was significant (64% [95% confidence interval 21, 82], P < .01). Adverse events were reported in all 3 treatment arms: 31 (86%) had an adverse event, 7 (19%) had a serious adverse event, and 15 (42%) had an adverse event of special interest with no difference between treatment arms. Significance: This randomized trial was underpowered because of incomplete enrollment, yet it demonstrated that cosyntropin was more effective for short-term outcomes than vigabatrin as initial treatment for infantile spasms.


  • The Missed Value of Underutilizing Pediatric Epilepsy Surgery: A Systematic Review

    by Christopher W. Beatty, Jason P. Lockrow, Satyanarayana Gedela, Alison Gehred, Adam P. Ostendorf


  • Epileptic Spasms Predict Poor Epilepsy Outcomes After Perinatal Stroke

    by Jason P. Lockrow, Jason N. Wright, Russell P. Saneto, Catherine Amlie-Lefond

    Perinatal stroke is a significant cause of severe epilepsy, including epileptic spasms. Although epileptic spasms due to underlying structural lesion often respond poorly to treatment and evolve into drug-resistant epilepsy, outcomes are not uniformly poor, and predictors of outcomes are not well described. We performed a single-institution retrospective review of epileptic spasms following perinatal stroke to determine if outcome depended on vascular subtype. We identified 24 children with epileptic spasms due to perinatal ischemic stroke: 11 cases of perinatal arterial stroke and 13 cases of perinatal venous infarct. Initial response to treatment was similar between groups; however, although children with perinatal arterial stroke who responded to epileptic spasms therapy had high rates of seizure freedom, many children with perinatal venous infarct, regardless of initial response, had residual drug-resistant epilepsy. We consider whether the mechanism for epileptogenesis may be different between arterial and venous strokes, and whether these 2 groups should be monitored for epileptic spasms, and subsequent epilepsy, differently.